Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study

SEXCHECK - Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06458764

Acronym

SEXCHECK

Enrollment

150

Registered

2024-06-14

Start date

2023-05-01

Completion date

2025-12-01

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Female, Premenopausal Breast Cancer, Sexual Dysfunction

Brief summary

Primary objectives: * To estimate Sexual Dysfunction (SD) incidence in premenopausal breast cancer patients treated by surgery and taking endocrine therapy. * To detect the presence of SD-related distress in the population, as a determining factor in the maintenance of a good quality of life. Secondary objectives: * To describe SD characteristics determining the most frequently reported symptoms and correlations with type of surgery or therapeutic regimens. * Collect baseline data for subsequent randomized trials involving practical interventions with the aim to reduce SD prevalence in this population.

Interventions

OTHERQuestionnaire

none, it's a incidence-prevalence study

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* women aged ≥18 and ≤ 55 * who underwent surgery for early stage breast cancer * taking endocrine therapy for at least 3 months * providing an informed consent and completing the study questionnaires.

Exclusion criteria

* withdrawal of the informed consent, at any time

Design outcomes

Primary

Measure	Time frame	Description
Sexual Dysfunction (SD) incidence	6 months	To estimate Sexual Dysfunction (SD) incidence (physiological parameter) in premenopausal breast cancer patients treated by surgery and taking endocrine therapy.
SD-related distress	6 months	To detect the presence of SD-related distress (physiological parameter) in the population, as a determining factor in the maintenance of a good quality of life.

Secondary

Measure	Time frame	Description
SD characteristics	6 months	To describe SD characteristics determining the most frequently reported symptoms and correlations with type of surgery or therapeutic regimens.
Collect baseline data	6 months	Collect baseline data for subsequent randomized trials involving practical interventions with the aim to reduce SD prevalence in this population.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026